SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (389)2/23/2000 1:27:00 PM
From: scaram(o)uche  Respond to of 3557
 
Chuckle.

Two good things are happening.

1. Most of the companies that reached ridiculous valuations are back-filling with gobs of offering-derived cash.

This helps to validate this new level of liquidity. While net valuations may be 10-15X, underlying capital is often now 10-20% of such.

2. Given these new, sustainable levels of capitalization and liquidity (not at the 10-15X, IMO, but up substantially), strong "older" companies are going off like popcorn.

Absolute heaven for the biotech investor.

<g>




To: nigel bates who wrote (389)2/23/2000 5:26:00 PM
From: Larry Liebman  Read Replies (1) | Respond to of 3557
 
Patience outs.
It is delicioulsy disorienting to remember the discussion less than a year ago when such luminaries as CBST, MEDX, NBIX, HYSQ, RZYM, etc., et al, ALL sold for $<4/sh; when posters dreamed of 10 baggers; when inspired analysts predicted the demise of micro-biotechs.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News